RxDoctor Payments Data

Leigh Segal, MD

Rheumatology · Bordentown, NJNPI 1679593644

Payments from drug & device makers

$1,864in general payments, 2019–2025

Across 124 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$578
  • Johnson & Johnson$157
  • Novartis$146
  • UCB, Inc.$145
  • Pfizer$139
  • Amgen$137
  • plus $563 from 14 others

What the payments were for

  • Speaking & faculty fees$35019%
  • Food & beverage$1,51481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,864 in reported general payments places this provider in the 40th percentile of 234 rheumatology providers in New Jersey.

See all rheumatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$339,724
Medicare patients
274
Services billed
15,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept75$577,649
EnbrelEtanercept73$565,040
Orencia ClickjectAbatacept43$245,307
SimponiGolimumab29$196,822
Xeljanz XrTofacitinib Citrate28$150,725
Humira(Cf)Adalimumab20$132,599
Humira(Cf) PenAdalimumab17$130,667
Actemra ActpenTocilizumab17$70,545
Cimzia (2 Pack)Certolizumab Pegol12$66,132
TymlosAbaloparatide23$60,246
OtezlaApremilast12$56,747
Teriparatide21$50,667
ProliaDenosumab26$45,856
Hydroxychloroquine Sulfate166$7,426
MethotrexateMethotrexate Sodium203$6,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla, Prolia$137$667,643111 claims
Johnson & JohnsonSimponi$157$196,82229 claims
AbbVieHumira(Cf)$578$132,59920 claims
UCB, Inc.Cimzia (2 Pack)$145$66,13212 claims
Radius Health, Inc.Tymlos$51$60,24623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 234 rheumatology providers in New Jersey.

Other rheumatology in Bordentown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →